Market Overview

Mylan Launches Generic Versions of Trilipix Caps

Related MYL
Mylan Wins Motion For Temporary Restraining Order Against Apotex For Authorized Generic Of Paxil CR
Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine CR Yo Apotex; Apotex Can No Longer Supply Authorized Generic Product
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg.

Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg, are the generic version of Abbott's Trilipix® Capsules, which are indicated as an adjunct to diet in combination with a statin to reduce triglyceride and increase high-density lipoprotein cholesterol in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Fenofibric Acid Delayed-release Capsules, 45 mg and 135 mg, had U.S. sales of approximately $553.6 million for the 12 months ending March 31, 2013, according to IMS Health.

Currently, Mylan has 174 ANDAs pending FDA approval representing $83.2 billion in annual sales, according to IMS Health. Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $22.9 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to IMS Health.

Posted-In: News

 

Most Popular

Related Articles (MYL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters